ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...

ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

ARS Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing solutions for patients with allergic reactions, particularly anaphylaxis, through innovative products like their ...

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key ...

In a pivotal development this year, the U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) in August 2024 for emergency use in type 1 allergic reactions, such as anaphylaxis.

Syracuse, N.Y. – A Syracuse man accused of helping his girlfriend hide her 5-year-old daughter’s dead body has been arrested on charges, prosecutors said Thursday. Corrice Parks, 28, is now ...

The Adrenaverse platform is a relatively new platform by Aquestive. This platform is essentially the 'secret-sauce' ...

We are convinced that neffy® will transform anaphylaxis, benefitting patients at risk and leading to a significant expansion of the market.” Exclusive rights to new indications ARS Pharma is ...